Stock 6628 TRANSCENTA HOLDING LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Company Transcenta Holding Limited

Equities

6628

KYG9005B1041

Pharmaceuticals

Market Closed - Hong Kong S.E.
Other stock markets
 04:08:20 2024-04-26 am EDT 		5-day change 1st Jan Change
1.78 HKD +1.71% Intraday chart for Transcenta Holding Limited +5.95% -50.42%
Apr. 09 Transcenta Partners with Agilent to Develop Claudin18.2 Companion Diagnostic MT
Apr. 09 Transcenta Holding Limited Announces Collaboration with Agilent Technologies to Develop a Claudin18.2 Companion Diagnostic to Support TranStar301 Global Phase III Trial CI

Business Summary

Transcenta Holding Limited is a China-based investment holding company engaged in the discovery, research, development, manufacturing and business development of biopharmaceuticals in the clinical stage. The Company's products include MSB2311, TST001, TST005, TST002, TST004, TST003, TST008, MSB0254 and TST006. The Company's all products are in the research and development (R&D) stage and have not been commercialized. The Company also provides contract developmentand manufacturing organization (CDMO) services, mainly including process development services, GMP / cGMP production services, cell line development services, sample testing services, formula optimization services and drug formation research.

Number of employees: 215

Sales per Business

HKD in Million2022Weight2023Weight Delta
Oncology and Non-oncology Therapeutics
100.0 %
118 100.0 % 60 100.0 % -49.78%

Sales per region

HKD in Million2022Weight2023Weight Delta
China
100.0 %
118 100.0 % 60 100.0 % -49.78%

Managers

Managers TitleAgeSince
Xue Ming Qian FOU
 Founder 57 10-07-31
Xiao Lu Weng DFI
 Director of Finance/CFO 47 21-12-16
Caroline Germa CTO
 Chief Tech/Sci/R&D Officer 52 22-08-07
Charlie Qi CTO
 Chief Tech/Sci/R&D Officer - 20-07-31
Yi Gu CTO
 Chief Tech/Sci/R&D Officer 55 19-01-31
Ming Shi CTO
 Chief Tech/Sci/R&D Officer 59 -
Christopher Hwang CTO
 Chief Tech/Sci/R&D Officer 61 16-09-30
Feng Ye COO
 Chief Operating Officer 57 15-12-31
Wei Wang IRC
 Investor Relations Contact 41 22-03-20
Agnes Dai HRO
 Human Resources Officer - 20-01-31

Members of the board

Members of the board TitleAgeSince
Yi Ning Zhao FOU
 Founder 53 18-11-30
Xue Ming Qian FOU
 Founder 57 10-07-31
Jia Song Tang BRD
 Director/Board Member 50 21-09-13
Zhi Hua Zhang BRD
 Director/Board Member 43 21-09-13
Ming Shi CTO
 Chief Tech/Sci/R&D Officer 59 -
Kumar Srinivasan BRD
 Director/Board Member 59 22-12-18
Xiao Lu Weng DFI
 Director of Finance/CFO 47 21-12-16
Wei Chen BRD
 Director/Board Member 57 23-08-22

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 436,375,375 391,500,827 ( 89.72 %) 0 89.72 %

Shareholders

NameEquities%Valuation
LAV Management Co., Ltd.
16.16 %
70,536,703 16.16 % 19 M $
China Structural Reform Fund Corp. Ltd.
9.034 %
39,421,012 9.034 % 10 M $
Xue Ming Qian
6.467 %
28,221,788 6.467 % 8 M $
Fullerton Fund Management Co. Ltd.
5.963 %
26,021,880 5.963 % 7 M $
Xiao Hong Shi
5.136 %
22,411,376 5.136 % 6 M $
Yi Ning Zhao
1.150 %
5,016,562 1.150 % 1 M $
Temasek Capital Pte Ltd.
0.4731 %
2,064,500 0.4731 % 548 682 $
Jun Bao
0.006875 %
30,000 0.006875 % 7 973 $
Kumar Srinivasan
0.006875 %
30,000 0.006875 % 7 973 $
Wei Chen
0.006875 %
30,000 0.006875 % 7 973 $

Company contact information

Transcenta Holding Ltd.

218 Xinghu Street B6-501, Biobay

215123, Suzhou

+

http://www.transcenta.com
address Transcenta Holding Limited(6628)

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Other Pharmaceuticals

Sales per region

Ratings for Transcenta Holding Limited

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
1.648 CNY
Average target price
7.58 CNY
Spread / Average Target
+360.04%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
TRANSCENTA HOLDING LIMITED Stock Transcenta Holding Limited
-50.42% 92.45M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 6628 Stock
  4. Company Transcenta Holding Limited